Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 5/2018

01-10-2018 | Research Article

Pharmacist’s interventions improve time in therapeutic range of elderly rural patients on warfarin therapy: a randomized trial

Authors: Slaven Falamić, Marko Lucijanić, Maja Ortner Hadžiabdić, Srećko Marušić, Vesna Bačić Vrca

Published in: International Journal of Clinical Pharmacy | Issue 5/2018

Login to get access

Abstract

Background Community pharmacists can play an important role in optimizing warfarin treatment, which is very important in vulnerable patient groups such as the elderly patients in rural areas. Objective To evaluate the impact of a community pharmacist’s interventions on the quality of anticoagulation in elderly rural patients receiving warfarin. Setting A community pharmacy in Donji Miholjac in Croatia’s province of Slavonia. Method We conducted a prospective randomized trial. Eligible patients were recruited at the pharmacy and randomized into two groups. All participants were followed up monthly for a period of 6 months. Repeated education and a follow up plan were provided to the participants in the intervention group, and their general practitioners were contacted to correct the warfarin dose or to avoid drug interactions. Main outcome measure Time in therapeutic range (TTR) calculated by the Rosendaal method. Results A total of 140 patients were randomized and 131 patients finished the study, 65 patients in the intervention group. Median age was 73 years. At the end of the follow-up period, the median TTR was significantly higher in the intervention group (93 vs. 31.2% for intervention and control, respectively; P < 0.001). The proportion of patients with TTR ≥ 65% was also significantly higher in the intervention group (86.2 vs. 7.6% for intervention and control, respectively; P < 0.001). Factors independently associated with TTR ≥ 65% were intervention (P < 0.001), less frequent dose change (P = 0.005), better adherence (P < 0.001) and less variable vitamin K intake (P = 0.010).
Literature
1.
go back to reference Capodanno D, Angiolillo DJ. Antithrombotic therapy in the elderly. J Am Coll Cardiol. 2010;56(21):1683–92.CrossRef Capodanno D, Angiolillo DJ. Antithrombotic therapy in the elderly. J Am Coll Cardiol. 2010;56(21):1683–92.CrossRef
2.
go back to reference Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41:67–76.CrossRef Klotz U. Pharmacokinetics and drug metabolism in the elderly. Drug Metab Rev. 2009;41:67–76.CrossRef
3.
go back to reference Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ. 2004;329(7456):15–9.CrossRef Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18,820 patients. BMJ. 2004;329(7456):15–9.CrossRef
4.
go back to reference Douthit N, Kiv S, Dwolatzky T, Biswas S. Exposing some important barriers to health care access in the rural USA. Pub Health. 2015;129:611–20.CrossRef Douthit N, Kiv S, Dwolatzky T, Biswas S. Exposing some important barriers to health care access in the rural USA. Pub Health. 2015;129:611–20.CrossRef
6.
go back to reference Harrison J, Shaw JP, Harrison JE. Anticoagulation management by community pharmacists in New Zealand: an evaluation of a collaborative model in primary care. Int J Pharm Pract. 2015;23:173–81.CrossRef Harrison J, Shaw JP, Harrison JE. Anticoagulation management by community pharmacists in New Zealand: an evaluation of a collaborative model in primary care. Int J Pharm Pract. 2015;23:173–81.CrossRef
7.
go back to reference Manji I, Pastakia SD, Do AN, Ouma MN, Schellhase E, Karwa R, et al. Performance outcomes of a pharmacist-managed anticoagulation clinic in the rural, resource-constrained setting of Eldoret, Kenya. J Thromb Haemost. 2011;9:2215–20.CrossRef Manji I, Pastakia SD, Do AN, Ouma MN, Schellhase E, Karwa R, et al. Performance outcomes of a pharmacist-managed anticoagulation clinic in the rural, resource-constrained setting of Eldoret, Kenya. J Thromb Haemost. 2011;9:2215–20.CrossRef
8.
go back to reference Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69(3):236–9.CrossRef Rosendaal FR, Cannegieter SC, van der Meer FJ, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost. 1993;69(3):236–9.CrossRef
9.
go back to reference Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest. 2008;133:160S–98S.CrossRef Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, Palareti G. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th Edition). Chest. 2008;133:160S–98S.CrossRef
10.
go back to reference Franco V, Polanczyk CA, Clausell N, Rohde LE. Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols. Am J Med. 2004;116(10):651–6.CrossRef Franco V, Polanczyk CA, Clausell N, Rohde LE. Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols. Am J Med. 2004;116(10):651–6.CrossRef
11.
go back to reference Lip GYH, Halperin JL. Improving stroke risk stratification in atrial fibrillation. Am J Med. 2010;123:484–8.CrossRef Lip GYH, Halperin JL. Improving stroke risk stratification in atrial fibrillation. Am J Med. 2010;123:484–8.CrossRef
12.
go back to reference Pisters R, Lane DA, Nieuwlaat R, De Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the euro heart survey. Chest. 2010;138:1093–100.CrossRef Pisters R, Lane DA, Nieuwlaat R, De Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the euro heart survey. Chest. 2010;138:1093–100.CrossRef
13.
go back to reference Maes KA, Studer H, Berger J, Hersberger KE, Lampert ML. Documentation of pharmaceutical care: validation of an intervention oriented classification system. J Eval Clin Pract. 2017;23(6):1425–32.CrossRef Maes KA, Studer H, Berger J, Hersberger KE, Lampert ML. Documentation of pharmaceutical care: validation of an intervention oriented classification system. J Eval Clin Pract. 2017;23(6):1425–32.CrossRef
14.
go back to reference Young S, Bishop L, Twells L, Dillon C, Hawboldt J, O’Shea P, et al. Comparison of pharmacist managed anticoagulation with usual medical care in a family medicine clinic. BMC Fam Pract. 2011;12:88.CrossRef Young S, Bishop L, Twells L, Dillon C, Hawboldt J, O’Shea P, et al. Comparison of pharmacist managed anticoagulation with usual medical care in a family medicine clinic. BMC Fam Pract. 2011;12:88.CrossRef
15.
go back to reference Entezari-Maleki T, Dousti S, Hamishehkar H, Gholami K. A systematic review on comparing 2 common models for management of warfarin therapy; pharmacist-led service versus usual medical care. J Clin Pharmacol. 2016;56:24–38.CrossRef Entezari-Maleki T, Dousti S, Hamishehkar H, Gholami K. A systematic review on comparing 2 common models for management of warfarin therapy; pharmacist-led service versus usual medical care. J Clin Pharmacol. 2016;56:24–38.CrossRef
16.
go back to reference Víquez-jaikel A, Hall-Ramírez V, Ramos-Esquivel A. Improvement of time in therapeutic range with warfarin by pharmaceutical intervention. Int J Clin Pharm. 2017;39(1):41–4.CrossRef Víquez-jaikel A, Hall-Ramírez V, Ramos-Esquivel A. Improvement of time in therapeutic range with warfarin by pharmaceutical intervention. Int J Clin Pharm. 2017;39(1):41–4.CrossRef
17.
go back to reference Saokaew S, Sapoo U, Nathisuwan S, Chaiyakunapruk N, Permsuwan U. Anticoagulation control of pharmacist-managed collaborative care versus usual care in Thailand. Int J Clin Pharm. 2012;34(1):105–12.CrossRef Saokaew S, Sapoo U, Nathisuwan S, Chaiyakunapruk N, Permsuwan U. Anticoagulation control of pharmacist-managed collaborative care versus usual care in Thailand. Int J Clin Pharm. 2012;34(1):105–12.CrossRef
18.
go back to reference Gallagher J, Mc Carthy S, Woods N, Ryan F, O’Shea S, Byrne S. Economic evaluation of a randomized controlled trial of pharmacist-supervised patient self-testing of warfarin therapy. J Clin Pharm Ther. 2015;40:14–9.CrossRef Gallagher J, Mc Carthy S, Woods N, Ryan F, O’Shea S, Byrne S. Economic evaluation of a randomized controlled trial of pharmacist-supervised patient self-testing of warfarin therapy. J Clin Pharm Ther. 2015;40:14–9.CrossRef
19.
go back to reference Clarkesmith DE, Pattison HM, Lip GY, Lane DA. Educational intervention improves anticoagulation control in atrial fibrillation patients: the TREAT randomised trial. PLoS ONE. 2013;8(9):e74037.CrossRef Clarkesmith DE, Pattison HM, Lip GY, Lane DA. Educational intervention improves anticoagulation control in atrial fibrillation patients: the TREAT randomised trial. PLoS ONE. 2013;8(9):e74037.CrossRef
20.
go back to reference Šupe S, Božina N, Matijević V, et al. Prevalence of genetic polymorphisms of CYP2C9 and VKORC1—implications for warfarin management and outcome in Croatian patients with acute stroke. J Neurol Sci. 2014;343(1–2):30–5.CrossRef Šupe S, Božina N, Matijević V, et al. Prevalence of genetic polymorphisms of CYP2C9 and VKORC1—implications for warfarin management and outcome in Croatian patients with acute stroke. J Neurol Sci. 2014;343(1–2):30–5.CrossRef
22.
go back to reference Mearns ES, White CM, Kohn CG, Hawthorne J, Song J-S, Meng J, et al. Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression. Thromb J. 2014;12:14.CrossRef Mearns ES, White CM, Kohn CG, Hawthorne J, Song J-S, Meng J, et al. Quality of vitamin K antagonist control and outcomes in atrial fibrillation patients: a meta-analysis and meta-regression. Thromb J. 2014;12:14.CrossRef
23.
go back to reference Fang MC, Go AS, Hylek EM, Chang Y, Henault LE, Jensvold NG, et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med. 2004;141(10):745–52.CrossRef Fang MC, Go AS, Hylek EM, Chang Y, Henault LE, Jensvold NG, et al. Advanced age, anticoagulation intensity, and risk for intracranial hemorrhage among patients taking warfarin for atrial fibrillation. Ann Intern Med. 2004;141(10):745–52.CrossRef
25.
go back to reference Penning-van Beest FJ, Koerselman J, Herings RMC. Quantity and quality of potential drug interactions with coumarin anticoagulants in the Netherlands. Pharm World Sci. 2007;29:671–5.CrossRef Penning-van Beest FJ, Koerselman J, Herings RMC. Quantity and quality of potential drug interactions with coumarin anticoagulants in the Netherlands. Pharm World Sci. 2007;29:671–5.CrossRef
26.
go back to reference Mazor KM, Baril J, Dugan E, Spencer F, Burgwinkle P, Gurwitz JH. Patient education about anticoagulant medication: is narrative evidence or statistical evidence more effective? Patient Educ Couns. 2007;69:145–57.CrossRef Mazor KM, Baril J, Dugan E, Spencer F, Burgwinkle P, Gurwitz JH. Patient education about anticoagulant medication: is narrative evidence or statistical evidence more effective? Patient Educ Couns. 2007;69:145–57.CrossRef
27.
go back to reference Nochowitz B, Shapiro NL, Nutescu EA, Cavallari LH. Effect of a warfarin adherence aid on anticoagulation control in an inner-city anticoagulation clinic population. Ann Pharmacother. 2009;43(7):1165–72.CrossRef Nochowitz B, Shapiro NL, Nutescu EA, Cavallari LH. Effect of a warfarin adherence aid on anticoagulation control in an inner-city anticoagulation clinic population. Ann Pharmacother. 2009;43(7):1165–72.CrossRef
28.
go back to reference Cryder B, Felczak M, Janociak J, Dela pena L, Allen S, Gutierrez P. Prevalent aetiologies of non-therapeutic warfarin anticoagulation in a network of pharmacist-managed anticoagulation clinics. J Clin Pharm Ther. 2011;36(1):64–70.CrossRef Cryder B, Felczak M, Janociak J, Dela pena L, Allen S, Gutierrez P. Prevalent aetiologies of non-therapeutic warfarin anticoagulation in a network of pharmacist-managed anticoagulation clinics. J Clin Pharm Ther. 2011;36(1):64–70.CrossRef
29.
go back to reference Tan KM, Tallon E, Noone I, Hughes G, O’Shea D. Crowe M Difficulties encountered by the very elderly with atrial fibrillation on warfarin attending an outpatient anticoagulant monitoring service. Eur Geriatr Med. 2012;3:78–81.CrossRef Tan KM, Tallon E, Noone I, Hughes G, O’Shea D. Crowe M Difficulties encountered by the very elderly with atrial fibrillation on warfarin attending an outpatient anticoagulant monitoring service. Eur Geriatr Med. 2012;3:78–81.CrossRef
30.
go back to reference Jackson SL, Peterson GM, Bereznicki LR, Misan GM, Jupe DM, Vial JH. Improving the outcomes of anticoagulation in rural Australia: an evaluation of pharmacist-assisted monitoring of warfarin therapy. J Clin Pharm Ther. 2005;30(4):345–53.CrossRef Jackson SL, Peterson GM, Bereznicki LR, Misan GM, Jupe DM, Vial JH. Improving the outcomes of anticoagulation in rural Australia: an evaluation of pharmacist-assisted monitoring of warfarin therapy. J Clin Pharm Ther. 2005;30(4):345–53.CrossRef
Metadata
Title
Pharmacist’s interventions improve time in therapeutic range of elderly rural patients on warfarin therapy: a randomized trial
Authors
Slaven Falamić
Marko Lucijanić
Maja Ortner Hadžiabdić
Srećko Marušić
Vesna Bačić Vrca
Publication date
01-10-2018
Publisher
Springer International Publishing
Published in
International Journal of Clinical Pharmacy / Issue 5/2018
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-018-0691-z

Other articles of this Issue 5/2018

International Journal of Clinical Pharmacy 5/2018 Go to the issue